Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Continuing Medical Education Questions: May 2026
Umar, Sarah B.

Mayo Clinic

American Journal of Gastroenterology | May 1, 2026 | Volume: 121 | Issue: 5 | Pages: 1069-1069

10.14309/ajg.0000000000004006 Get It

At‐home visual acuity in children using a custom iPhone application compared with standardized in‐office visual acuity testing
Roberts, Tawna L. , Bothun, Erick D. , Zhu, Yufeng, Henderson, Robert J. , Boyle, Nicole M, Leske, David A. , Wernimont, Suzanne M., Marino, Carrie E, Manh, Vivian M. , Youngerman, Jillian M, Qayum, Jennifer N, Srinivasan, Gayathri , Titelbaum, Jenna R. , Crouch, Eric R. , Colburn, Jeffrey, Esposito, Christina , Zeto, V Lori, Connolly, Katie, Bhakta, Rita M, Lorenzana, Ingryd J., McDowell, Paula, Beaulieu, Wesley T, Kraker, Raymond T, Holmes, Jonathan M, Pineles, Stacy L., Weise, Katherine K., Cotter, Susan A, Group, Pediatric Eye Disease Investigator, Beaulieu, Wesley T , Kraker, Raymond T , Hatt, Sarah R. , Raghuram, Aparna , McDowell, Paula S., Kraker, Raymond T. , Holmes, Jonathan M. , Cotter, Susan A.

Mayo Clinic

Optometry and Vision Science | May 1, 2026 | Volume: 103 | Issue: 4 | Pages: No page available

10.1002/ovs2.70040 | PMID 42062237 Get It

ABSTRACT Purpose To validate a custom smartphone application for at‐home visual acuity (VA) measurement in children. Methods A total of 452 children aged 3–17.5 years participated. Certified examiners measured in‐office test–retest VA (logMAR) using gold‐standard Amblyopia Treatment Study HOTV (3‐to‐6‐year‐olds, younger cohort) or electronic Early Treatment of Diabetic Retinopathy Study (7‐to‐17.5‐year‐olds, older cohort) protocols at 3–4.5 m and app‐based VA at 1.5 m. Caregivers measured at‐home app‐based VA at 1.5 m. Results Comparing at‐home app‐based with gold‐standard VA, in eyes 20/40 or better, 95% (143/151) and 93% (91/98) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = −0.03, older = −0.04; 95% limits‐of‐agreement half‐width (LOA): younger = ±0.26, older = ±0.22). In eyes 20/50 or worse, 66% (42/64) and 75% (76/101) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = 0.11, older = 0.13, LOA: younger = ±0.50, older = ±0.51). Comparing in‐office app‐based VA with gold‐standard VA, in eyes 20/40 or better, 98% (160/164) and 94% (99/105) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = −0.03, older = −0.03; LOA: younger = ±0.22; older = ±0.24). In eyes 20/50 or worse, 85% (60/71) and 91% (101/111) of the younger and older cohorts were within 2 lines, respectively (mean differences: younger = 0.04; older = 0.04; LOA: younger = ±0.39; older = ±0.24). For gold‐standard test–retest, in eyes 20/40 or better, 99% (163/164) and 99% (104/105) of the younger and older cohorts had retest within 2 lines, respectively (mean differences: younger = 0.00; older = 0.01; LOA: younger = ±0.17; older = ±0.11). For 20/50 or worse, 92% (66/72) and 100% (111/111) in the younger and older cohorts were within 2 lines, respectively (mean differences: younger = 0.01; older = 0.02; LOA: younger = ±0.35; older = ±0.15). Conclusions Our app demonstrated good concordance with the gold standard at home and in the office for eyes with VA of 20/40 or better. However, concordance decreased considerably for eyes with VA 20/50 or worse, particularly at home.
Abstract TU205: The Effect of Physical Activity on the Gut Microbiome in Prediabetes: Results from a Randomized Controlled Trial
Demmer, Ryan, Pope, Zachary, Avenido, Francis Ryan, Mitchell, Nathan, Hubbard, Paige Richmond, Johnson, Stephen, McDonough, DJ, Rydell, Sarah, Johnson, Abigail, Pereira, Mark, Demmer, Ryan T. , Pope, Zachary , Mitchell, Nathan R , Hubbard, Paige F. Richmond, Johnson, Stephen, Sharma, Shweta , Rydell, Sarah A.

Mayo Clinic

Circulation | April 30, 2026 | Volume: 153 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.153.suppl_1.tu205 Get It

Objective: To test the effect of physical activity on the gut microbiome and circulating short chain fatty acids among sedentary overweight/obese adults with prediabetes. We hypothesized that randomization to increased physical activity would result in gut microbiome changes. Methods: \We randomized 77 adults with prediabetes and a sedentary lifestyle into one of two groups: 1) Intervention Group: Invited to engage in home-based moderate intensity walking 3x/week for 30 minutes/session in weeks 1-4 and for 45 minutes/session during weeks 5-8 of the 8-week intervention; or 2) Control Group: Maintained habitual physical activity levels. We performed metagenomic sequencing from stool collected at baseline, week 4, and week 8, with short-chain fatty acids (SCFA) measured from serum collected at baseline and week 8. Taxonomic and functional profiling were performed on the metagenomic reads; alpha diversity metrics were subsequently derived. Linear regression assessed the difference in change between the intervention and control groups for alpha-diversity and SCFA levels. Results: We screened 1,533 participants for eligibility and consented 132. Of these, 87 entered the run-in phase and 77 were randomized. Participants were 51.4±8.9 years old, 87.7% female, and 74% non-Hispanic White. Mean fasting glucose was 103.3±13.2 while mean BMI was 34.4±5.7. In comparison to the control group, the intervention group experienced decreased alpha diversity as characterized by Shannon, Richness, and Faith’s diversity indices by week 8 of the intervention (P<0.05). SCFA levels trended towards improvement in the intervention group, but the results were not statistically significant. Functional analysis of KEGG ontologies revealed themes consistent with a microbiome with enhanced metabolic activity and host-relevant metabolic signaling (Figure). Conclusions: Randomization to a walking intervention resulted in modest gut microbiome changes among adults with overweight/obesity and prediabetes.
Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers
Benveniste, Pierre‐Louis , Létourneau‐Guillon, Laurent , Araújo, David , Fetco, Dumitru , Hori, Masaaki , Kamiya, Kouhei , Messina, Steven, Audoin, Bertrand , Blezek, Daniel, Brisset, Jean‐Christophe , Charlson, Erik, Chen, Michelle , Demortière, Sarah , Edan, Gilles , Filippi, M, Kerbrat, Anne , Kirschke, J, Labauge, Pierre, Liu, Yaou, Mainero, Caterina , Medina, Nilser Laines , Reich, Daniel S. , Shepherd, Timothy M. , Smith, Seth A. , Talbott, Jason, Tauhid, Shahamat , Treaba, Constantina A. , Cohen-Adad, Julien, Fetco, Dumitru , Hori, Masaaki , Audoin, Bertrand , Bakshi, Rohit , Bannier, Elise , Blezek, Daniel , Brisset, Jean-Christophe , Callot, Virginie , Chen, Michelle , Ciccarelli, Olga , Edan, Gilles , Filippi, Massimo , Granberg, Tobias , Granziera, Cristina , Hemond, Christopher C , Keegan, B Mark , Kerbrat, Anne , Kirschke, Jan , Kollind, Shannon H , Lee, Lisa Eunyoung , McGinnis, Julian , Laines Medina, Nilser , Mühlau, Mark , Nair, Govind , O'Grady, Kristin P , Oh, Jiwon , Ouellette, Russell , Reich, Daniel S , Rocca, Maria A , Smith, Seth A , Stawiarz, Leszek , Tam, Roger , Traboulsee, Anthony , Treaba, Constantina Andrada , Valsasina, Paola , Yiannakas, Marios , Cohen-Adad, Julien , Guillon, Laurent Letourneau , Chougar, Lydia , Messina, Steven A. , Tsagkas, Charidimos , Blezek, Daniel J. , Ciccarelli, Olga , Filippi, Massimo , Keegan, B. Mark , Labauge, Pierre , Lee, Lisa Eunyoung , Nair, Govind , O’Grady, Kristin P. , Prat, Alexandre , Rocca, Maria A. , Talbott, Jason F. , Tam, Roger , Lombaert, Hervé

Mayo Clinic

Multiple Sclerosis Journal | April 24, 2026 | Volume: 32 | Issue: 6 | Pages: 598-613

10.1177/13524585261427333 | PMID 42028790 Get It

Background/Objectives: Characterizing spinal cord multiple sclerosis (MS) lesions in MRI is critical for diagnosis, monitoring, and treatment evaluation. However, current automated approaches for lesion detection and segmentation are typically designed for specific MRI contrasts or acquisition sites, limiting their generalizability in real-world clinical settings where imaging protocols vary widely. This work proposes a robust multi-site, multi-contrast segmentation framework for spinal cord lesions. Methods: The segmentation model was trained and evaluated on a large-scale dataset comprising 4428 annotated images from 1849 persons with MS across 23 imaging centers, encompassing six MRI contrasts (T1w, T2w, T2*w, PSIR, STIR, and UNIT1) acquired at 1.5 tesla (T), 3 T, and 7 T. Results: Likert-type assessment performed by neuroradiologist ratings demonstrated superior generalization of the model compared to existing contrast-specific pipelines ( p < 0.01). Additional experiments evaluated robustness across spinal levels, acquisition resolutions, binarization thresholds, and quantitative evaluation on external labeled datasets. Conclusions: The proposed model can achieve accurate and reliable spinal cord MS lesion segmentation across heterogeneous MRI data, addressing a key barrier to clinical translation. The model is available in the Spinal Cord Toolbox v7.2 and higher. Code repository: https://github.com/ivadomed/seg-sc-ms-lesion-multicontrast
Improving Care by FAster risk-STratification through use of high sensitivity point-of-care troponin in patients presenting with possible acute coronary syndrome in the EmeRgency department (ICare-FASTER): a stepped-wedge cluster randomized trial
Than, Martin , Pickering, John W. , Buchan, Vanessa A, Florkowski, Christopher M , Mills, Nicholas L. , Hamill, Laura , Prystowsky, Jason, Harger, Simon, Reed, Mary, Bayless, Jared, Feberwee, Alexander, Attenburrow, Tamsin, Norman, Timothy, Welfare, Oliver, Heiden, Tamika L., Kavsak, Peter, Jaffe, Allan S. , Apple, Fred S. , Cullen, L, Aldous, Sally, Frampton, Christopher MA, Body, Richard, Lord, Sarah Jane, George, Peter Myles, Devlin, Gerard, Kavsak, Peter A. , Mills, Nicholas L , Than, Martin , Pickering, John W , Joyce, Laura R, Buchan, Vanessa, Florkowski, Christopher M , Hamill, Laura, Prystowsky, Jason, Harger, Simon, Reed, Mary, Bayless, Jared, Feberwee, Alexander, Attenburrow, Tamsin, Norman, Timothy, Welfare, Oliver, Heiden, Tamika, Kavsak, Peter , Jaffe, Allan S. , Apple, Fred S. , Peacock, William Frank , Cullen, Louise , Aldous, Sally, Richards, Arthur M , Lacey, Cameron, Troughton, Richard W , Frampton, Christopher, Body, Rick , Mueller, Christian , Lord, Sarah, George, Peter M, Devlin, Gerard

Mayo Clinic

No container title available | April 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.21.26351433 Get It

ABSTRACT BACKGROUND Point-of-care (POC) high-sensitivity cardiac troponin (hs-cTn) testing has the potential to expedite decision-making and reduce emergency department (ED) length of stay for patients presenting with possible myocardial infarction (MI) by ensuring that results are consistently available when looked for by clinicians. We assessed the real-life effectiveness and safety of implementing POC hs-cTn testing in the ED. METHODS We conducted a pragmatic, stepped-wedge cluster randomized trial. The control arm was usual care with an accelerated diagnostic pathway utilizing a single-sample rule-out step with a central laboratory hs-cTn assay. The intervention arm used the same pathway with a POC hs-cTnI. The primary effectiveness outcome was ED length of stay assessed using a generalized linear mixed model, and the safety outcome was 30-day MI or cardiac death. RESULTS Six sites participated with 59,980 ED presentations (44,747 individuals, 61±19 years, 49.5% female) from February 2023 to January 2025, in which 31,392 presentations were during the intervention arm. After adjustment for co-variates associated with length of stay, the intervention reduced length of stay by 13% (95% confidence intervals [CI], 9 to 16%. P<0.001), corresponding to a reduction of 47 minutes (95%CI, 33 to 61 minutes) from a mean length of stay in the control arm of 376 minutes. The 30-day MI or cardiac death rate was similar in the control and intervention arms (0.39% and 0.39% respectively, P=0.54). CONCLUSIONS Implementation of whole-blood hs-cTnI testing at the POC into an accelerated diagnostic pathway was safe and reduced length of stay in the ED compared with laboratory testing. (Australia New Zealand Clinical Trials Registry ACTRN12619001189112) Clinical Perspective What is new? Point-of-care troponin assays with good precision have become available and received regulatory approval as high-sensitivity assays. A pragmatic stepped-wedge cluster randomized trial implementing the validated Siemens VTLi high-sensitivity point-of-care assay into 6 emergency departments investigating ∼60,000 patients, was conducted to ascertain if the rapid turnaround time reduced lengths of stay. Introduction of the VTLi high-sensitivity point-of-care assay into clinical pathways reduced emergency department lengths of stay by an average 13% (47 minutes) without compromising safety. What are the clinical implications? Early decision-making using a point-of-care high-sensitivity troponin assay within a structured clinical pathway was safe. Faster turnaround means troponin results are consistently available when clinicians first seek them. This can facilitate earlier decisions and reduce patient length of stay.
Lymphocyte dynamics after CAR ‐T therapy for non‐Hodgkin lymphoma
Dingli, Sarah , Rothweiler, Paul , Corraes, Andre De Menezes Silva, Atallah‐Yunes, Suheil Albert , Ansell, Stephen M. , Bennani, N Nora, Johnston, Patrick B., Khurana, Arushi , Paludo, Jonas, Bisneto, J. C. Villasboas, Wang, Y, Lin, Yi, Erdman, Arthur G. , Atallah-Yunes, Albert , Durani, Urshila , Wang, Yucai , Erdman, Arthur G , Dingli, David , Corraes, Andre De Menezes Silva , Bennani, N. Nora , Durani, Urshila , Johnston, Patrick B. , Paludo, Jonas , Bisneto, J.C.C. Villasboas, Lin, Yi, Dingli, David

Mayo Clinic

British Journal of Haematology | April 21, 2026 | Volume: 209 | Issue: 1 | Pages: 189-196

10.1111/bjh.70502 | PMID 42011548 Get It

Summary Chimeric antigen receptor T cells directed against CD‐19 are highly effective therapies for various subtypes of B‐cell non‐Hodgkin lymphoma (NHL). We have studied the impact of patient‐specific lymphocyte growth kinetics after lymphoid depletion chemotherapy on both long‐term outcomes and toxicity in patients with diffuse large B‐cell non‐Hodgkin lymphoma (DLBCL). The growth of the lymphocyte populations early after chimeric antigen receptor T‐cell (CAR‐T) therapy is well described by an exponential function and the growth rate of the cells appears to be one of the most critical determinants of overall survival in these patients. The maximum lymphocyte peak and the area under curve for lymphocytes within the first 4 weeks after CAR‐T therapy had no impact on survival. Receiver operator characteristic analysis determined that a replication rate ≥0.3876/day is associated with superior rates of complete response and durable responses. This threshold is associated with higher grades of cytokine release syndrome and the need for tocilizumab. However, patients with this threshold have a median overall survival of 3.04 years compared to 1.035 years for patients with slower lymphocyte replication ( p = 0.0206). The major determinant of depth of response and durability of response to CAR‐T in NHL is the speed of lymphocyte expansion.
Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention
Harrison, Theresa M., Harvey, Danielle J., Chadwick, Trevor, Chao, Yishu , Taggett, Jacinda , Maillard, Pauline, Lovato, Laura, Farias, Sarah, Papp, Kathryn V., Lockhart, Samuel N., Toga, Arthur W., Koeppe, Robert A., Jagust, William J., Whitmer, Rachel A., Snyder, Heather M. , Carrillo, Maria C., Baker, Laura D. , Espeland, Mark A., Vemuri, Prashanthi, DeCarli, Charles, Landau, Susan M., Harvey, Danielle , Carrillo, María C. , Harvey, Danielle J , Harrison, Theresa M. , Maillard, Pauline , Lovato, Laura, Farias, Sarah Tomaszewski , Papp, Kathryn V. , Lockhart, Samuel N. , Toga, Arthur W. , Koeppe, Robert A. , Jung, Youngkyoo , Jagust, William J. , Whitmer, Rachel A. , Espeland, Mark Andrew , Vemuri, Prashanthi , DeCarli, Charles , Landau, Susan

Mayo Clinic

JAMA Neurology | April 20, 2026 | Volume: 83 | Issue: 6 | Pages: 521

10.1001/jamaneurol.2026.0832 | PMID 42008251 Get It

Importance Brain imaging biomarkers may (1) identify underlying mechanisms of intervention effects and (2) define brain characteristics of those most likely to benefit cognitively from the intervention. Objective To test whether (1) a lifestyle intervention is related to brain changes, (2) brain changes are correlated with intervention-specific cognition changes, and (3) brain imaging biomarkers provide information about who is likely to benefit from a lifestyle intervention. Design, Setting, and Participants In this randomized clinical trial, the POINTER Imaging study was an ancillary study of the 2-year, single-blind multicenter US POINTER clinical trial in which neuroimaging data were collected on eligible enrolled participants. The study was conducted from May 2019 to March 2023 (final follow-up, May 14, 2025). Participants were enrolled into the POINTER Imaging study following a standard procedure at 5 clinical sites in the US. Participant eligibility criteria included an age of 60 to 79 years, sedentary lifestyle, and suboptimal diet, plus at least 2 additional risk criteria for cognitive decline and no contraindications for neuroimaging. Interventions Participants were randomly assigned to receive the structured or self-guided intervention. Both interventions emphasized increased physical and cognitive activity, healthy nutrition, social engagement, and cardiovascular health monitoring, but they differed in intensity and accountability. Main Outcomes and Measures There were 4 primary imaging outcomes: global β-amyloid (Aβ) burden, tau burden in the entorhinal cortex (ERC), hippocampal (HC) volume, and white matter hyperintensity volume. The primary cognitive measure was a global cognitive composite. Results Among 1943 parent trial participants who were assessed for eligibility, 983 underwent at least 1 magnetic resonance imaging or positron emission tomography scanning session. The mean (SD) age was 68.4 (5.2) years; 605 participants (61.5%) were female and 378 male (38.5%). Five hundred sixteen participants received the structured intervention and 467 the self-guided intervention. There were no intervention group differences in longitudinal cognitive or imaging outcomes. Intervention group differences were not associated with or moderated by Aβ status or accumulation. There was a negative association between change in ERC tau and change in global cognition in the self-guided group that was attenuated in the structured group (difference in association: 0.289; 95% CI, 0.029 to 0.550; interaction P = .03). Lower baseline HC volume was associated with greater cognitive benefit for participants in the structured group vs the self-guided group (lower HC: 0.077 SD; 95% CI, 0.022 to 0.132; higher HC: 0.002 SD; 95% CI, −0.037 to 0.041; interaction P = .03). Conclusion and Relevance This study found that a high-intensity multidomain lifestyle intervention did not affect brain biomarker trajectories and was not associated with Aβ pathology, but older adults with specific at-risk brain characteristics, including lower baseline HC volume, showed a greater cognitive benefit of the structured intervention. Trial Registration ClinicalTrials.gov Identifier: NCT03688126
Human iPSC-Derived Dorsal Root Ganglion Organoid Modeling of Chemotherapy-Induced Peripheral Neuropathy
Hrstka, Sybil , Jahnke, Maya, Meng-Lin, Kylie, Lindorfer, Sarah, Noma, Henry, Hrstka, Ronald F., Staff, Nathan P. , Hrstka, Sybil C , Staff, Nathan P

Mayo Clinic

Cells | April 20, 2026 | Volume: 15 | Issue: 8 | Pages: 724

10.3390/cells15080724 | PMID 42041591 Get It

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity affecting 30–40% of patients treated with neurotoxic chemotherapy. Sensory symptoms arise from injury to dorsal root ganglion (DRG) neurons and their axons; yet, the underlying mechanisms remain incompletely understood. While human induced pluripotent stem cell (iPSC)-derived sensory neuron (iSN) monolayers have provided mechanistic insight, they lack the three-dimensional architecture and cellular heterogeneity of native DRG tissue. Here, we generated human iPSC-derived DRG organoids (iDRGOs) containing mixed neuronal and peripheral glial populations and established a quantitative neurite outgrowth assay to model chemotherapy-induced neurotoxicity in a 3D context. iDRGOs from three healthy donors were exposed to bortezomib, vincristine, or paclitaxel. All three drugs caused dose-dependent neurite outgrowth impairment without significant short-term changes in organoid size, consistent with early axonal injury. Vincristine reduced MAP2 levels when normalized to total protein, whereas bortezomib and paclitaxel showed divergent microtubule-associated responses compared to monolayer cultures. The developmental stage significantly influenced the baseline neurite outgrowth, highlighting the need for age standardization. These results establish iDRGOs as a physiologically relevant human platform that complements monolayer models for mechanistic studies and therapeutic screening in CIPN.
Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia
Banerjee, Ritu, Komarow, Lauren , Li, Yixuan, Mau, Donald, Geres, Holly, Greenwood-Quaintance, Kerryl, Adler, Amos , Baliga, S, Chrysos, George , Zarkotou, Olympia , Paul, Mical, Regueiro, Dolores Sousa, Chambers, Henry, Fowler, Vance G., Patel, Robin, Group, Antibacterial Resistance Leadership, Chambers, Henry F. , Cross, Heather, Harris, Anthony D. , Duin, David van, Boucher, Helen W., Huntley, Clayton C., Raterman, Erica L., Samuel, Tamika, Moon, Kyung, Holland, Thomas L., Lodise, Thomas, Shelburne, Samuel A. , Cosgrove, Sara E., Lautenbach, Ebbing , Mehigan, Maureen, Doernberg, Sarah B. , Perdue, Sam, Singh, Tara A. , Wickward, Cathy, Souto, David A., Waller, Jason, Evans, Scott R , Banerjee, Ritu , Dodd, Andrew, Geres, Holly, Greenwood‐Quaintance, Kerryl E. , Baliga, Shrikala , Chowers, Michal , Paul, Mical, Pournaras, Spyros , Fowler, Vance G. , Patel, Robin , Evans, Scott , Hamasaki, Toshimitsu , Pettigrew, Melinda M. , Hanson, Kimberly E. , Doi, Yohei , Holland, Thomas L. , Cosgrove, Sara E. , Paterson, David L.

Mayo Clinic

JAMA | April 18, 2026 | Volume: 335 | Issue: 20 | Pages: 1762

10.1001/jama.2026.5487 | PMID 41999287 Get It

Importance Novel blood culture diagnostics provide rapid antimicrobial susceptibility testing (AST) results for bacteria causing bloodstream infections (BSIs) but have unclear clinical impact. Objective To evaluate clinical outcomes of blood culture testing using a rapid AST method compared with standard AST in patients with BSIs caused by gram-negative bacilli in regions with high prevalence of antimicrobial resistance. Design, Setting, and Participants Open-label randomized clinical trial that enrolled participants from December 2023 to May 2025 (final follow-up, June 18, 2025) at 7 medical centers in Greece (n = 2), India (n = 1), Israel (n = 3), and Spain (n = 1). Hospitalized patients (adults and children) with BSIs caused by gram-negative bacilli were eligible. Statistical analysis was conducted from August 2025 to January 2026. Intervention Patients were randomized to undergo blood culture evaluation using rapid, phenotypic AST directly from positive blood cultures plus standard susceptibility testing (n = 413) vs standard susceptibility testing alone (n = 437). Local antimicrobial stewardship teams reviewed all patients and provided treatment recommendations. Main Outcomes and Measures The primary outcome was a desirability of outcome ranking (DOOR) at day 30, with 3 categories (alive without deleterious events, alive with deleterious events, and death). The difference between rapid and standard testing was summarized as the probability that the DOOR outcomes were more desirable in the rapid testing group. Superiority was concluded if the lower limit of the 95% CI exceeded 50%. Secondary outcomes included 30-day mortality, length of hospitalization, intensive care unit admission, acquisition of hospital-acquired infections, time to effective antibiotic therapy within 3 days, and time to antibiotic escalation or deescalation within 3 days. Results Of the 899 patients randomized, 850 were included in the primary outcome analysis (median [IQR] age, 72 [21] years; 43% female). The probability that DOOR outcomes were more favorable in the rapid testing group was 48.8% (95% CI, 45.3%-52.4%). Median time to effective antibiotic therapy was not different between the groups in the as-randomized population. Median time to antibiotic escalation or deescalation was faster in the rapid testing group by 14 hours (95% CI, 6-22) in the as-randomized population. There were no differences between the groups in other secondary outcomes. In the prespecified subgroup with carbapenem-resistant infections, median time to effective therapy was 9.5 hours in the rapid testing group vs 28 hours in the standard testing group (difference, −18 hours [95% CI, −42 to 6]). Conclusions and Relevance Among patients with gram-negative bacilli BSIs, rapid blood culture AST was not superior to standard testing by DOOR. When considered with other efficacy and safety outcomes, these findings may help inform the use of rapid susceptibility testing in clinical practice. Trial Registration ClinicalTrials.gov Identifier: NCT06174649